Dr. Juan Antonio Navarro Langa

Emerging Investigator
Research Group on Cellular and Organic Physiopathology of Oxidative Stress

Presentation

Dr. Navarro has a Bachelor and a PhD degree in Chemistry from the University of Valencia. He studied Biochemistry where he became interested in the processes that occur in the mitochondria and how their dysfunction triggers cause neurological and neuromuscular diseases. His scientific career and his research focus on the use of Drosophila melanogaster as a translational biomedical tool to study and unveil the molecular mechanisms underpinning rare neurodegenerative diseases such as Friedreich’s Ataxia (AF) or Hereditary Spastic Paraparesis (HSP7). Recently, Dr. Navarro has been awarded with the I3 certification from the Incentive Program for the Incorporation and Intensification of Research Activity of the Ministry of Science and Innovation.

After completing his doctorate, Juan Antonio started a postdoctoral position at the University of Regensburg in the chair of Professor Dr. Stephan Schneuwly. During this period, he combined over a decade his research activity with his role as Coordinator of the Master of International Excellence in Neurosciences carried out at the University of Regensburg.

In August 2020, he joined INCLIVA and the Group of Cellular and Organic Pathophysiology of Oxidative Stress led by Professor Federico V. Pallardó as Senior Postdoctoral Researcher thanks to the GenT Program funded by the Conselleria de Sanidad Universal y Salud Pública from Generalitat Valenciana.

Currently his lines of research are focused on deciphering the mechanism of programmed death followed by frataxin-deficient cells in FA patients. His hypothesis centers on a new form of cell death called ferroptosis. In addition, together with Dr. Filippo M. Santorelli from the University of Pisa he is trying to establish a translational research and diagnostic platform in the field of Drosophila-based hereditary spastic paraparesis. Finally, very recently, he has obtained funding from the Insituto de Salud Carlos III to start a new research project based on the repurposing of an old drug as a treatment for Neurodegenerative diseases based on PolyGlutamine expansions.

Dr. Juan Antonio Navarro Langa
Emerging
Investigator
Dr. Juan Antonio Navarro Langa

juan.a.navarro@uv.es

Publications
Phosphorylated resveratrol as a protein aggregation suppressor in vitro and in vivo. Mehringer J, Navarro J, Touraud D, Schneuwly S, Kunz W. Rsc Chemical Biology. 2022 Jan 4;3(2):250-260. doi: 10.1039/d1cb00220a. PMID: 35360889

Rabphilin silencing causes dilated cardiomyopathy in a Drosophila model of nephrocyte damage. Selma-Soriano E, Casillas-Serra C, Artero R, Llamusi B, Navarro J, Redon J. Scientific Reports. 2021 Jul 27;11(1):15287. doi: 10.1038/s41598-021-94710-7. PMID: 34315987

Projects
Reference: PI22/00507
Title: Reposicionamiento de fármacos como tratamiento para la enfermedad de Huntington y la ataxia espinocerebelosa de tipo 3. Estudios en cultivos primarios de pacientes y en modelos animales transgénicos.
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Federico V. Pallardó Calatayud, Juan Antonio Navarro Langa
Duration: 2023 – 2025
Total budget: 147.620,00 €
Reference: 2021095290
Title: Intracellular iron deposits in a Drosophila Model of Friedreich´s Ataxia
Funding body: Center of Excellence ALBA synchrotron
Principal Investigator: Juan Navarro Langa
Duration: 2022 – 2022
Total budget: 51.471 €
Reference: AP-2021-014
Title: FlyAvatar: Drosophila melanogaster como herramienta de diagnóstico molecular para la Paraparesia Espástica Hereditaria 7 (HSP7)
Funding body: Universidad de Valencia – INCLIVA
Principal Investigator: Mª José Martínez Sebastián, Juan Antonio Navarro Langa
Duration: 2021 – 2022
Total budget: 4.750 €
Reference: CDEI0420C
Title: Plan GenT: Drosophila melanogaster as model to study the impact of ferroptosis in Friedreich´s Ataxia
Funding body: Conselleria de Sanidad
Principal Investigator: Juan Navarro Langa
Duration: 2020 – 2023
Total budget: 246.500 €